Table 2.
The comprehensive list of the pharmacological activities from S. tonkinensis.
Detail | Extracts/Compounds | In Vivo/In Vitro | Active Concentration/Dose | References |
---|---|---|---|---|
Anti-inflammatory activity | ||||
Reduce TNF-α | (−)-Anagyrine (61) | In vitro | 50 µM | [12] |
Sophocarpine (34) | In vitro | 50 µM | [12] | |
14β-Hydroxymatrine (28) | In vitro | 50 µM | [12] | |
7β-Sophoramine (49) | In vitro | 50 µM | [12] | |
Matrine (1) | In vivo | 50 µM | [12] | |
(+)-5α-Hydroxymatrine (5) | In vivo | 50 µM | [12] | |
12,13-Dehydrosophoridine (16) | In vitro | 50 µM | [23] | |
13α-Hydroxymatrine (36) | In vitro | 50 µM | [23] | |
13β-Hydroxymatrine (37) | In vitro | 50 µM | [23] | |
Isosophocarpine (48) | In vitro | 50 µM | [23] | |
Sophoridine (13) | In vitro | 50 µM | [23] | |
Water extract of roots | In vivo | 0.3 g/kg | [75] | |
Inhibit the production of NO | sophoratonkin (189) | In vitro | IC50 = 33.0 µM | [28] |
Maackiain (168) | In vitro | IC50 = 27.0 µM | [28] | |
Sophoranone (120) | In vitro | IC50 = 28.1 µM | [28] | |
Sophoranochromene (144) | In vitro | IC50 = 13.6 µM | [28] | |
Tonkinochromane A (143) | In vitro | 20 µM | [45] | |
Flemichin D (139) | In vitro | 20 µM | [45] | |
6,8-Diprenyl-7,4′-dihydroxyflavanone (119) | In vitro | IC50 = 12.21 µM | [45] | |
Water extract of roots | In vivo | 100 mg/kg | [13] | |
Non-alkaloid extracts of roots | In vivo | 400 mg/kg | [13] | |
Reduce IL- 6 | 2′-Hydroxyglabrol (131) | In vitro | IC50 = 1.62 µM | [47] |
Glabrol (121) | In vitro | IC50 = 0.73 µM | [47] | |
Maackiain (168) | In vitro | IC50 = 3.01 µM | [47] | |
Bolusanthin IV (261) | In vitro | IC50 = 4.02 µM | [47] | |
Ethanol extract of roots | In vivo | 100 mg/kg | [7] | |
(−)-Anagyrine (61) | In vitro | 50 µM | [12] | |
Sophocarpine (34) | In vitro | 50 µM | [12] | |
14β-Hydroxymatrine (28) | In vitro | 50 µM | [12] | |
7β-Sophoramine (49) | In vitro | 50 µM | [12] | |
Matrine (1) | In vitro | 50 µM | [12] | |
(+)-5α-Hydroxyoxymatrine (3) | In vivo | 50 µM | [12] | |
(+)-5α-Hydroxymatrine (5) | In vivo | 50 µM | [12] | |
12,13-Dehydrosophoridine (16) | In vitro | 50 µM | [23] | |
13α-Hydroxymatrine (36) | In vitro | 50 µM | [23] | |
13β-Hydroxymatrine (37) | In vitro | 50 µM | [23] | |
Isosophocarpine (48) | In vitro | 50 µM | [23] | |
Sophoridine (13) | In vitro | 50 µM | [23] | |
Water extract of roots | In vivo | 0.3 g/kg | [75] | |
Reduce IL-5 | 50% (v/v) ethanol-water mixture | In vivo | 100 mg/kg | [76] |
Reduce IL-10 | Ethanol extract of roots | In vivo | 100 mg/kg | [7] |
Reduce IL-1β | Water extract of roots | In vivo | 0.3 g/kg | [75] |
Reduced the hyperplasia of goblet cell | 50% (v/v) ethanol-water mixture | In vivo | 10 mg/kg | [76] |
Inhibit xylene induced auricle swelling in mice | Oxymatrine (4) | In vivo | 40 mg/kg | [78] |
(−)-Cytisine (50) | In vivo | 40 mg/kg | [78] | |
S. tonkinensis particles | In vivo | 1.75 g/kg | [79] | |
Inhibit pain induced by acetic acid stimulation of the celiac mucosa | Matrine (1) | In vivo | 40 mg/kg | [78] |
Sophoridine (13) | In vivo | 30 mg/kg | [78] | |
Sophocarpine (34) | In vivo | 40 mg/kg | [78] | |
S. tonkinensis particles | In vivo | 3.5 g/kg | [79] | |
Inhibit croton oil induced ear swelling in mice | Water extract of roots | In vivo | 0.35–1.12 g/kg | [80] |
Ethanol extract of roots | In vivo | 0.35–1.12 g/kg | [80] | |
Water extract of roots | In vivo | 0.39 g/kg | [81] | |
Anti-tumor activity | ||||
Inhibit A549 | (−)-N-hexanoylcytisine (55) | In vitro | IC50 = 31.64 µM | [24] |
(−)-N-Formylcytisine (52) | In vitro | IC50 = 22.05 µM | [24] | |
(6aR, 11aR)-Maackiain (168) | In vitro | IC50 = 24.58 µM | [24] | |
Water extracts of roots | In vitro | 6.5 µg/µL | [82] | |
1-(6,7-Dihydro-5H-pyrrolo [1,2-a] imidazol-3-yl) ethenone (76) | In vitro | IC50 = 23.05 ± 0.46 µM | [27] | |
Inhibit HL-60 | Tonkinensisol (93) | In vitro | IC50 = 36.48 μg/mL | [15] |
Sophoranol (5) | In vitro | 10.00 µg/mL | [83] | |
13,14-Dehydrosophoranol (24) | In vitro | 1.00 µg/m L | [83] | |
Inhibit HepG2 | Tonkinensine C (73) | In vitro | IC50 = 87.4 ± 7.1 µM | [1] |
Perlolyrine (74) | In vitro | IC50 = 91.8 ± 3.5 µM | [1] | |
Harmine (72) | In vitro | IC50 = 48.9 ± 5.2 µM | [1] | |
Alkaloids | In vitro | IC50 = 9.04 g/L | [84] | |
Non-alkaloids extract of roots | In vitro | IC50 = 0.98 g/L | [84] | |
Water extracts of roots | In vitro | 6.5 µg/µL | [82] | |
Inhibit SH-SY5Y | Sophoranone (120) | In vitro | IC50 = 18.49 µM | [85] |
Matrine (1) | In vitro | IC50 = 60.81 µM | [85] | |
Oxymatrine (4) | In vitro | IC50 = 42.56 µM | [85] | |
(−)-Trifolirhizin (190) | In vitro | IC50 = 72.11 µM | [85] | |
(−)-Maackiain (168) | In vitro | IC50 = 65.62 µM | [85] | |
Inhibit B16-BL6 | Extract of roots | In vitro | 400 µg/mL | [86] |
Inhibit CNE-1, CNE-2 | Chloroform extract of roots | In vitro | 25 µg/mL | [87] |
Inhibit U937 | Sophoranone (120) | In vitro | IC50 = 3.8 ± 0.9 µM | [88] |
Inhibit HeLa | Tonkinensine B (59) | In vitro | IC50 = 24.3± 0.3 µM | [25] |
Inhibit MDA-MB-231 | Tonkinensine B (59) | In vitro | IC50 = 48.9± 0.5 µM | [25] |
Water extract of roots | In vitro | 6.5 µg/µL | [82] | |
Inhibit ESC solid tumor cell | Total alkaloids of roots | In vivo | 100 mg/kg | [89] |
Inhibit H22 ascites tumor cells | Total alkaloids of roots | In vivo | 100 mg/kg | [89] |
Inhibit S180 solid tumor cell | Total alkaloids of roots | In vivo | 75 mg/kg | [89] |
Inhibit BV2 glioma cell lines | Sophotokin (174) | In vitro | 10 µM | [34] |
Maackiain (168) | In vitro | 10 µM | [34] | |
Medicarpin (176) | In vitro | 10 µM | [34] | |
Inhibit Hep3B and KG-1 cells | Water extract of roots | In vitro | 6.5 µg/µL | [82] |
Decrease the number of cancer nodules in tumor tissue and reduce AFP in serum | Alkaloids extract of roots | In vivo | 0.036 g/kg | [90] |
Effects on the liver | ||||
Protect HepG2 cell against acetaminophen (APAP)- induced damage | 4-Methoxybenzamide (252) | In vitro | 10 µmol/L | [64] |
7,3’-Dihydroxy-8,4’-dimethoxyisoflavone (104) | In vitro | 10 µmol/L | [64] | |
7,4’-Dihydroxy-3’-methoxyisoflavone (102) | In vitro | 10 µmol/L | [64] | |
(±)-3-(p-Methoxyphenyl)-1,2-propanediol (255) | In vitro | 10 µmol/L | [64] | |
Enhance L-02 hepatocytes | Matrine (1) | In vivo and vitro | 10 µM | [91] |
Oxymatrine (4) | In vivo and vitro | 10 µM | [91] | |
Increase SOD and GSH | Non-alkaloids extract of roots | In vivo | 400 mg/kg | [13] |
Water extract of roots | In vivo | 400 mg/kg | [13] | |
Increase ALT and AST | Water extract of roots | In vivo | 0.59 g/kg | [92] |
Increase CPT 1A activity | Water extract of roots | In vivo | 25 μg/mL | [91] |
Reduce nonestesterified fatty acid Induce cellular lipids accumulation in hepatocytes | Matrine (1) | In vivo | 10 µM | [91] |
Oxymatrine (4) | In vivo | 10 µM | [91] | |
Reduce immune liver injury | Oxymatrine (4) | In vivo | 60 mg/kg | [93] |
Sophocarpine (34) | In vivo | 60 mg/kg | [93] | |
Oxymatrine (4) | In vivo | 120 mg/kg | [94] | |
Inhibite acetaminophen-induced hepatic oxidative damage in mice | STRP1 (Polysaccharide part) | In vivo | 200 mg/kg | [95] |
STRP2 (Polysaccharide part) | In vivo | 200 mg/kg | [95] | |
Alleviate non-alcoholic fatty liver disease of mice | Water extract of roots | In vivo | 90 mg/kg | [91] |
Inhibit the production of tyrosinase | Formononetin-7-O-β-D-glucoside(116) | In vitro | IC50 = (7.82 ± 0.28) × 10−4 mol/L | [43] |
Tectorigenin (112) | In vitro | IC50 = (3.73 ± 0.45) × 10−4 mol/L | [43] | |
8-Prenylkeamferol (91) | In vitro | IC50 = (1.58 ± 0.31) × 10−5 mol/L | [43] | |
Reduce AST and ALT | Oxymatrine (4) | In vivo | 120 mg/kg | [93] |
Sophocarpine (34) | In vivo | 120 mg/kg | [93] | |
Water extract of roots | In vivo | 0.25 g/kg | [96] | |
Reduce AST | Non-alkaloid extract of roots | In vivo | 100 mg/kg | [13] |
Water extract of roots | In vivo | 200 mg/kg | [13] | |
Reduce ALT | Non-alkaloid extracts of roots | In vivo | 400 mg/kg | [13] |
Water extract of roots | In vivo | 200 mg/kg | [13] | |
Anti-viral activity | ||||
Anti-Coxsackie virus B3 | (−)-12β-Hydroxyoxysophocarpine (18) | In vitro | IC50 = 26.62 µM | [14] |
(−)-9α-Hydroxysophocarpine (25) | In vitro | IC50 = 197.22 µM | [14] | |
(+)-Sophoranol (5) | In vitro | IC50 = 252.18 µM | [14] | |
(−)-14β-Hydroxymatrine (28) | In vitro | IC50 = 184.14 µM | [14] | |
3-(4-Hydroxyphenyl)- 4- (3- methoxy- 4-hydroxyphenyl)-3,4-dehydroquinolizidine (75) | In vitro | IC50 = 6.40 µM | [26] | |
Cermizine C (70) | In vitro | IC50 = 3.25 µM | [26] | |
Jussiaeiine A (68) | In vitro | IC50 = 4.66 µM | [26] | |
Jussiaeiine B (67) | In vitro | IC50 = 3.21 µM | [26] | |
(+)-5α-Hydroxyoxysophocarpine (17) | In vitro | IC50 = 0.12 µM | [26] | |
(−)-12β-Hydroxyoxysophocarpine (18) | In vitro | IC50 = 0.23 µM | [26] | |
(−)-Clathrotropine (64) | In vitro | IC50 = 1.60 µM | [26] | |
Anti-tobacco mosaic virus (TMV) | Sophtonseedlin B (188) | In vitro | 100 µg/mL | [56] |
(−)-Trifolirhizin (190) | In vitro | 100 µg/mL | [56] | |
Sophtonseedline B (21) | In vitro | 100 µg/mL | [19] | |
Sophtonseedline D (23) | In vitro | 100 µg/mL | [19] | |
Sophtonseedline F (8) | In vitro | 100 µg/mL | [19] | |
(−)-N-Formylcytisine (52) | In vitro | 100 µg/mL | [19] | |
Alkaloid extracts of seeds | In vitro | 0.5 mg/mL | [19] | |
Methanol extracts of seeds | In vitro | 0.5 mg/mL | [19] | |
Anti-hepatitis B virus (HBV) | (+)-Oxysophocarpine (20) | In vitro | 0.4 µmol/mL | [20] |
(−)-Sophocarpine (34) | In vitro | 0.4 µmol/mL | [20] | |
(+)-Lehmannine (14) | In vitro | 0.4 µmol/mL | [20] | |
(−)-13,14-Dehydrosophoridine (16) | In vitro | 1.6 µmol/mL | [20] | |
(−) -14β-Hydroxyoxymatrine (6) | In vitro | 0.4 µmol/mL | [18] | |
(+)-Sophoranol (5) | In vitro | 0.2 µmol/mL | [18] | |
(−)-Cytisine (50) | In vitro | 0.2 µmol/mL | [18] | |
Anti-mouse hepatitis virus | Methanol extracts of plant | In vitro | EC50 = 27.5 ± 1.1 µg/mL | [97] |
Inhibited influenza virus A/Hanfang/359/95 | (+)-12α-Hydroxysophocarpine (15) | In vitro | IC50 = 84.70 µM | [14] |
(−)-12β-Hydroxysophocarpine (19) | In vitro | IC50 = 242.46 µM | [14] | |
(+)-Sophoramine (49) | In vitro | IC50 = 63.07 µM | [14] | |
Anti-oxidant capacity | ||||
ABTS free radical scavenging ability | Chloroform extract of roots | In vitro | EC50 = 1.08 mg/mL | [98] |
Ethyl acetate extract of roots | In vitro | EC50 = 0.55 mg/mL | [98] | |
N-butanol extract of roots | In vitro | EC50 = 1.27 mg/mL | [98] | |
Ethanol extract of roots | In vitro | EC50 = 3.08 mg/mL | [98] | |
Shandougenines A (263) | In vitro | IC50 = 0.532 ± 0.076 mM | [40] | |
Shandougenines B (264) | In vitro | IC50 = 0.18 ± 0.032 mM | [40] | |
Bolusanthin IV (261) | In vitro | IC50 = 0.3 ± 0.025 mM | [40] | |
2-(2′,4′-Dihydroxyphenyl)-5,6-methylenedioxybenzofuran (260) | In vitro | IC50 = 0.726 ± 0.041 mM | [40] | |
Shandougenine C (127) | In vitro | IC50 = 0.382 ± 0.055 mM | [40] | |
Shandougenine D (128) | In vitro | IC50 = 0.341 ± 0.058 mM | [40] | |
Demethylmedicarpin (179) | In vitro | IC50 = 0.503 ± 0.036 mM | [40] | |
Scavenging of DPPH radicals | Ethyl acetate extract of roots | In vitro | 0.5 mg/mL | [98] |
Ethanol extract of roots | In vitro | 0.5 mg/mL | [98] | |
Chloroform extract of roots | In vitro | 0.5 mg/mL | [98] | |
N-butanol extract of roots | In vitro | 0.5 mg/mL | [98] | |
Water extract of aerial parts | In vitro | IC50 = 0.1434 g/L | [17] | |
N-butyl alcohol extract of aerial parts | In vitro | IC50 = 0.0754 g/L | [17] | |
Ethyl acetate extract of aerial parts | In vitro | IC50 = 0.0693 g/L | [17] | |
Dichloromethane of aerial parts | In vitro | IC50 = 0.0494 g/L | [17] | |
Petroleum ether extract of aerial parts | In vitro | IC50 = 0.1218 g/L | [17] | |
STRP1 (Polysaccharide part) | In vitro | 1.0 mg/mL | [95] | |
STRP2 (Polysaccharide part) | In vitro | 1.0 mg/mL | [95] | |
Tonkinensisol (93) | In vitro | IC50 = 0.616 ± 0.021 mM | [40] | |
Bolusanthin IV (261) | In vitro | IC50 = 0.502 ± 0.101 mM | [40] | |
2-(2′,4′-Dihydroxyphenyl)-5,6-methylenedioxybenzofuran (260) | In vitro | IC50 = 0.527 ± 0.054 mM | [40] | |
Shandougenines A (263) | In vitro | IC50 = 1.213 ± 0.101 mM | [40] | |
Shandougenines B (264) | In vitro | IC50 = 0.327 ± 0.022 mM | [40] | |
WRSP-A2b (Polysaccharide part) | In vitro | IC50 = 19.95 ± 0.25 mg/mL | [99] | |
WRSP-A3a (Polysaccharide part) | In vitro | IC50 = 5.99 ± 0.20 mg/mL | [99] | |
Reducing power | Chloroform extract of roots | In vitro | EC50 = 0.60 mg/mL | [98] |
Ethyl acetate extract of roots | In vitro | EC50 = 0.64 mg/mL | [98] | |
N-butanol extract of roots | In vitro | EC50 = 0.51 mg/mL | [98] | |
Ethanol extract of roots | In vitro | EC50 = 0.84 mg/mL | [98] | |
Hydroxyl radical scavenging ability | Chloroform extract of roots | In vitro | EC50 = 1.33 mg/mL | [98] |
Ethyl acetate extract of roots | In vitro | EC50 = 2.80 mg/mL | [98] | |
N-butanol extract of roots | In vitro | EC50 = 5.00 mg/mL | [98] | |
WRSP-A2b (Polysaccharide part) | In vitro | IC50 = 19.78 ± 0.47 mg/mL | [99] | |
WRSP-A3a (Polysaccharide part) | In vitro | IC50 = 8.38 ± 0.18 mg/mL | [99] | |
Superoxide anion radical scavenging ability | WRSP-A2b (Polysaccharide part) | In vitro | IC50 = 4.24 ± 0.11 mg/mL | [99] |
WRSP-A3a (Polysaccharide part) | In vitro | IC50 = 1.94 ± 0.05 mg/mL | [99] | |
Toxicity | ||||
Respiratory depression, muscle fibrillation, convulsions, spasms, and death | Hydroalcoholic extract from the roots | Mice (i.g.) | LD50 = 9.802 ± 2.0067 g/kg | [100] |
Convulsions, hair erection, rapid abdominal contraction and excitement, depression, abdominal breathing and eye closure, and death | (−)- Cytisine (50) | Mice (i.g.) | LD50 = 48.16 mg/kg | [101] |
Irritability, hyperactivity, shortness of breath, and convulsions | Water extract of roots | Mice (i.g.) | LD50 = 17.469 g/kg | [102] |
90% Ethanol extract of roots | Mice (i.g.) | LD50 = 27.135 g/kg | [102] | |
Alkaloids of roots | Mice (i.g.) | LD50 = 13.399 g/kg | [102] | |
Water and 70% Ethanol extract mixture of roots | Mice (i.g.) | MTD = 36 g/kg | [103] | |
All-component of of roots | Mice (i.g.) | MTD = 10.68 g/kg | [102] | |
Slow heartbeat, bent trunk of zebrafish, accelerated movement frequency, and abnormal movement track, Hepato renal, pericardial enlargement, death. | Sophoranone (120) | Zebrafish (p.o.) | LC50 = 22.45 µmol/L | [104] |
To cause hepatomegaly | Sophoranone (120) | Zebrafish (p.o.) | 3.86 µmol/L | [104] |
The zebrafish liver lost transparency and became dark or brown, and liver blood flow was no longer observable | Dealkalized water extract of roots | Zebrafish (p.o.) | LC10 = 1009.1 µg/mL | [105] |
Ethanol sedimentation extract of roots | Zebrafish (p.o.) | LC10 = 4367.6 µg/mL | [105] | |
N-Butyl ethanol extract of roots | Zebrafish (p.o.) | MNLC = 700.0 µg/mL | [105] | |
Slowed heart rate, reduced blood flow, and absence of circulation in the cardiotoxic phenotype, neurotoxic, and presents with behavioral abnormalities, bent trunk. | Sophoranone (120) | Zebrafish (p.o.) | 11.59 µmol/L | [104] |
Induced pericardial edema and slowed the blood circulation, heart rate lower | Diethyl ether extract of roots | Zebrafish (p.o.) | LC10 = 93.6 µg/mL | [105] |
N-Butyl ethanol extract of roots | Zebrafish (p.o.) | LC10 = 538.3 µg/mL | [105] | |
Pericardial edema, a misshaped atrium and ventricle as well as reduced number of endothelial cells and cardiomyocytes | Dichloromethane extract of roots | Zebrafish (p.o.) | MNLC = 450.0 µg/mL | [105] |
Delayed yolk sac resorption in the hepatotoxic phenotype and Intestinal dysplasia | Sophoranone (120) | Zebrafish (p.o.) | 1.29 µmol/L | [104] |
To cause renal and pericardial edema | Sophoranone (120) | Zebrafish (p.o.) | 15.57 µmol/L | [104] |
Other pharmacological activities | ||||
Inhibit Pseudomonas aeruginosa | 2’,4’,7-Trihydroxy-6,8-bis(3-methyl-2-butenyl) flavanone (259) | In vitro | MIC = 125.0 µg/mL | [16] |
Genistin (115) | In vitro | MIC = 15.6 µg/mL | [16] | |
Inhibit Bacillus megaterium | 2-Methoxy-6-methyl-1,4-benzoquinone (277) | In vitro | MIC = 3.125 µg/mL | [65] |
Xylariphilone (282) | In vitro | MIC = 12.5 µg/mL | [65] | |
Xylarphthalide A (283) | In vitro | MIC = 25 µg/mL | [67] | |
(−)-5-Carboxylmellein (280) | In vitro | MIC = 25 µg/mL | [67] | |
(−)-5-Methylmellein (281) | In vitro | MIC = 25 µg/mL | [67] | |
Inhibit Escherichia coli | Lanatine A (65) | In vitro | MIC = 1.0 g/L | [26] |
Jussiaeiines A (68) | In vitro | MIC = 3.2 g/L | [26] | |
Jussiaeiines B (67) | In vitro | MIC = 0.8 g/L | [26] | |
(−)-5-Carboxylmellein (280) | In vitro | MIC = 25 µg/mL | [67] | |
21-Acetoxycytochalasin J3 (304) | In vitro | MIC = 12.5 µg/mL | [71] | |
2-(2’,4’-Dihydroxy)-5,6-dioxomethylbenzofuran (260) | In vitro | MIC = 31.3 µg/mL | [16] | |
Xylarphthalide A (283) | In vitro | MIC = 25 µg/mL | [67] | |
(−)-5-Methylmellein (281) | In vitro | MIC = 25 µg/mL | [67] | |
6-Heptanoyl-4-methoxy-2H-pyran-2-one (286) | In vitro | MIC = 50 µg/mL | [106] | |
Inhibit Staphylococcus aureus | 3-(4-Hydroxyphenyl)-4-(3-methoxy-4-hydroxyphenyl) -3,4-dehydroquinolizidine (75) | In vitro | MIC = 8.0 g/L | [26] |
Cermizines C (70) | In vitro | MIC = 3.5 g/L | [26] | |
Jussiaeiines B (67) | In vitro | MIC = 6.0 g/L | [26] | |
Cytochalasin K (311) | In vitro | MIC = 12.5 µg/mL | [65] | |
6-Heptanoyl-4-methoxy-2H-pyran-2-one (286) | In vitro | MIC = 50 µg/mL | [106] | |
(−) -N-methylcytisine (54) | In vitro | MIC = 12.0 g/L | [26] | |
Xylarphthalide A (283) | In vitro | MIC = 25 µg/mL | [67] | |
(−)-5-Carboxylmellein (280) | In vitro | MIC = 25 µg/mL | [67] | |
(−)-5-Methylmellein (281) | In vitro | MIC = 12.5 µg/mL | [67] | |
Cytochalasin K (311) | In vitro | MIC = 12.5 µg/mL | [65] | |
2’,4’,7-Trihydroxy-6,8-bis(3-methyl-2-butenyl) flavanone (259) | In vitro | MIC = 62.5 µg/mL | [16] | |
Ethyl acetate extract of roots | In vitro | MIC = 0.313 mg/mL | [98] | |
Inhibit Shigella dysenteriae | Xylarphthalide A (283) | In vitro | MIC = 25 µg/mL | [67] |
(−)-5-Methylmellein (281) | In vitro | MIC = 25 µg/mL | [67] | |
(−)-3-Carboxypropyl-7-hydroxyphthalide (293) | In vitro | MIC = 12.5 µg/mL | [69] | |
Inhibit Proteus vulgaris | Xylareremophil (287) | In vitro | MIC = 25 µg/mL | [68] |
Mairetolide G (291) | In vitro | MIC = 25 µg/mL | [68] | |
Inhibit Micrococcus luteus | Mairetolide G (291) | In vitro | MIC = 50 µg/mL | [68] |
Mairetolide B (290) | In vitro | MIC = 50 µg/mL | [68] | |
Xylareremophil (287) | In vitro | MIC = 25 µg/mL | [68] | |
Inhibit Micrococcus lysodeikticus | Mairetolide B (290) | In vitro | MIC = 100 µg/ml | [68] |
Mairetolide G (291) | In vitro | MIC = 100 µg/mL | [68] | |
Xylareremophil (287) | In vitro | MIC = 100 µg/mL | [68] | |
Inhibit Bacillus subtilis | (−)-5-Carboxylmellein (280) | In vitro | MIC = 12.5 µg/mL | [67] |
Mairetolide B (290) | In vitro | MIC = 100 µg/mL | [68] | |
Mairetolide G (291) | In vitro | MIC = 100 µg/mL | [68] | |
Xylarphthalide A (283) | In vitro | MIC = 25 µg/mL | [67] | |
(−)-5-Methylmellein (281) | In vitro | MIC = 12.5 µg/mL | [67] | |
Xylapeptide A (301) | In vitro | MIC = 12.5 µg/mL | [70] | |
(−)-3-Carboxypropyl-7-hydroxyphthalide (293) | In vitro | MIC = 25 µg/mL | [69] | |
Xylareremophil (287) | In vitro | MIC = 100 µg/mL | [68] | |
Inhibit Bacillus anthracis | (−)-5-Carboxylmellein (280) | In vitro | MIC = 25 µg/mL | [67] |
21-Acetoxycytochalasin J3 (304) | In vitro | MIC = 12.5 µg/mL | [71] | |
Inhibit Alternaria oleracea | Cytochalasin E (310) | In vitro | MIC = 3.125 µg/mL | [71] |
Cytochalasin H (306) | In vitro | MIC = 6.25 µg/mL | [71] | |
Inhibit Colletotrichum capsici | Cytochalasin E (310) | In vitro | MIC = 1.56 µg/mL | [71] |
Cytochalasin H (306) | In vitro | MIC = 6.25 µg/mL | [71] | |
Inhibit Pestalotiopsis theae | Cytochalasin E (310) | In vitro | MIC = 1.56 µg/mL | [71] |
Cytochalasin H (306) | In vitro | MIC = 12.5 µg/mL | [71] | |
Inhibit Enterobacter areogenes | (−)-3-Carboxypropyl-7-hydroxyphthalide methyl ester (294) | In vitro | MIC = 12.5 µg/mL | [69] |
(−)-3-Carboxypropyl-7-hydroxyphthalide (293) | In vitro | MIC = 12.5 µg/mL | [69] | |
Inhibit Colletotriehum gloeosporioides | Methanol extract of roots | In vitro | EC50 = 1.214 mg/mLMIC = 2.5 mg/mL | [107] |
Inhibit Fusarium solani | Methanol extract of roots | In vitro | EC50 = 1.169 mg/mLMIC = 2.5 mg/mL | [107] |
Inhibit Ceratocystis paradoxa | Cytochalasin H (306) | In vitro | MIC = 25 µg/mL | [71] |
Inhibit Bacillus cereus | Xylapeptide A (301) | In vitro | MIC = 12.5 µg/mL | [70] |
Moderate activities against Aphis fabae | Sophtonseedline G (9) | In vivo | LC50 = 38.29 mg/L | [19] |
Matrine (1) | In vivo | LC50 = 18.63 mg/L | [19] | |
(−)-N-Formylcytisine (52) | In vivo | LC50 = 23.74 mg/L | [19] | |
Decreased fasting blood glucose levels | Matrine (1) | In vivo | 2.5 mg/kg | [108] |
Ethyl acetate extract of roots | In vivo | 60 mg/kg | [33] | |
alleviate insulin resistance | Ethyl acetate extract of roots | In vivo | 60 mg/kg | [33] |
Matrine (1) | In vivo | 10 mg/kg | [108] | |
Inhibit 5-lipoxygenase | 50 % (v/v) Ethanol–water mixture | In vitro | IC50 = 1.61 µg/mL | [76] |
Maackiain (168) | In vitro | IC50 = 7.9 µM | [76] | |
Sophoranone (120) | In vitro | IC50 = 1.6 µM | [76] | |
Inhibit thromboxane synthase | 50 % (v/v) Ethanol–water mixture | In vitro | IC50 = 5.56 µg/mL | [76] |
Inhibit butyrylcholinesterase | Ethanol extract of roots | In vitro | IC50 = 15. 169 µg/mL | [109] |